Cytori slashes jobs following clinical hold; Clal sues Hyperion over Andromeda scandal; Threshold shares slide as TH-302 study continues past interim;

@FierceBiotech: If you missed yesterday's live #Fierce15 announcement, catch the replay from @partnering360Watch | Follow @FierceBiotech

@JohnCFierce: Fun watching the inversion news bend from "Oh no!" to "Hey, wait a minute" this morning. Maybe not the kiss of death after all? | Follow @JohnCFierce

@DamianFierce: Fierce15 winner Molecular Partners just filed to raise ~$134M in a Swiss IPO. | Follow @DamianFierce

> Weeks after the FDA put a pair of clinical studies of its stem cell therapy on hold, Cytori has come back and slashed 42 jobs in a reorganization aimed at eliminating $8 million in annual expenses. And the company executive vice president for marketing and sales is departing in the restructuring. The San Diego-based biotech says it will have a staff of 77 after the layoffs. CEO Marc Hedrick said that the company's lenders waived a liquidity threshold on cash balances, adding that the company is now working on restructuring the loan. The hold was imposed after several cases of cerebrovascular events. Cytori makes a regenerative concoction out of fat tissue, extracting stem cells from patients which are then injected into patients to treat various medical conditions. Release

> Not long after Hyperion ($HPTX) says it was bamboozled by Andromeda Biotech with falsified drug data, the former parent company of the Israeli biotech--Clal--is firing back in a $200 million lawsuit, saying Hyperion acted unreasonably in shuttering the trial. Story

> Shares of Threshold Pharmaceuticals ($THLD) slid on Monday as investors reacted to the news that its TH-302 study for soft tissue sarcoma would continue past the interim analysis and on to its conclusion. Merck KGaA bought into the drug and now considers this program one of its top pipeline prospects. Release

Medical Device News

@FierceMedDev: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story via FierceDrugDelivery | Follow @MichaelGFierce

@VarunSaxena2: In case you're wondering, $MDT can cancel its deal with $COV without penalty if it's due to changes in the tax code. Wonder what will happen. | Follow @VarunSaxena2

@EmilyWFierce:  T2 Biosystems wins FDA approval for sepsis diagnostic system. More | Follow @EmilyWFierce

> Philips splits in two, making HealthTech its sole priority. News

> Ivantis gets $71M for glaucoma device, while Minerva secures $21M to reduce menstrual bleeding. Article

Pharma News

@FiercePharma: Allergan rebuffed Actavis bid, saying it's 'closing in' on a $10B-plus Salix buy. Story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. Article via FiercePharmaManufacturing | Follow @EricPFierce

> Faltering Boehringer slashes 600 jobs in Germany in bid to save $580M. Story

> Heads will roll at GlaxoSmithKline, investors say. The question is, whose? Article

> Tax-deal crackdown's victims, say analysts? Mylan and Abbott, not Pfizer and AZ. News

Biotech Research News

> Researchers develop tumor-on-a-chip to test new cancer drugs. Article

> Genetic 'switch' may control aging process. News

> Drug development for tropical diseases gets $15.3M boost. Item

> Pathway discovery reveals another potential Alzheimer's drug target. Article

> New technique generates stem cells at highly efficient rate. Story

Pharma Manufacturing News

> GSK accidentally dumps 'liquid contaminated with poliovirus' into Belgian sewer system. Report

> Ritedose to invest up to $110M in South Carolina plant. Article

> Recall of Mylan nitroglycerin revised to avoid shortage. Story

> GSK influenza plant in Texas on track to start up in 2016. Item

> Merck KGaA deal for Sigma-Aldrich gets it some specialty manufacturing capacity. More

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.